在阿尔茨海默氏病连续体中,中性粒细胞与淋巴细胞的比例
Davide Aprile1, Fabiola De Marchi1, Federico Menegon1
1Neurology Unit, Department of Translational Medicine, Università del Piemonte Orientale (UPO), 28100 Novara, Italy.
International journal of molecular sciences
|June 13, 2025
概括
中性粒细胞与淋巴细胞比率 (NLR) 是一种血液检测标志物,与阿尔茨海默病 (AD) 的进展和神经炎症有关. 需要进一步的研究来证实其在早期阿尔茨海默病诊断和治疗中的临床使用.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物标志物研究 生物标志物研究
背景情况:
- 阿尔茨海默病 (AD) 的特点是认知能力下降和神经炎症.
- 周围生物标志物对于了解AD的炎症机制至关重要.
- 中性粒细胞与淋巴细胞的比率 (NLR) 是一个有前途的全身炎症标志物.
研究的目的:
- 审查NLR和AD在疾病谱中之间的关联.
- 评估NLR作为AD的诊断和预后工具的潜力.
- 讨论NLR在AD研究中的临床实用性和局限性.
主要方法:
- 对研究的综合文献综述 检查在AD和轻度认知障碍 (MCI) 中的NLR.
- 分析了NLR水平,疾病严重程度,粉样蛋白负担和神经炎症之间的关系.
- 在AD群体中影响NLR的混因素的评估.
主要成果:
- 升高的NLR与AD和MCI有关,与疾病严重程度和神经炎症相关.
- 增加的中性粒细胞可以通过氧化应激和炎症驱动神经退行.
- 淋巴细胞减少表明在阿尔茨海默病中适应性免疫力受损.
结论:
- NLR显示出作为AD相关炎症的具有成本效益的标记物的潜力.
- 研究中的异质性和混因素需要谨慎地解释NLR的临床实用性.
- 未来的研究应该专注于纵向研究和针对个性化的AD策略的综合生物标志物方法.
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171


